Skip to main content
Grant Churchill on Muck Rack

Grant Churchill

As seen in: BioRxiv, Cell Press

Get in touch with Grant

Contact Grant, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Grant Churchill’s Biography

Read Full Bio →

SEO firms ensure that guaranteed Search Engine Optimization solutions consist of the Google's webmaster guidelines. Web-master standards boost site rank as well as search activity. Click this link: http://www.openbroadcast.de/article/146466/citrix-mit-frost-amp-sullivan-2011-global-market-penetration-leadership-award-ausgezeichnet.html for more information.

Articles

Rational discovery of therapeutic PAK1 allosteric activators

|
By Yu He, James Bae, Carlos Outeiral, Daniel A. Nissley, Anthony Tumber, Georgina Berridge, Eidarus Salah, Yi Wang, Wenqi He, Hongyuan Zhang, Tangting Chen, Samuel E. Tusk, Sebastian Mathea, Ying-Jie Wang, Alexander Grassam-Rowe, Philipp Kukura, Christopher J Schofield, Darragh O’Brien, Andrea Pierangelini, Grant Churchill, Thomas Lanyon-Hogg, Yunbo Ke, Chao Xu, Tao Ye, Hugh Watkins, Liming Ying, Andreas Koschinski, R. John Solaro, Xiaoqiu Tan, Jani R. Bolla, Xin Wang, Stefan Knapp, Charlotte M. Deane, Manuela Zaccolo, Marcin Nowotny, Ming Lei
| Cell Press Verified
Peptide synthesis PAK1 activating peptide (PAP) TSNSQKYMSFTDKSA was prepared as previously described.28 Briefly, PAP derived from the PAK1 autoinhibitory region was linked to the 11-amino acid sequence YGRKKRRQRRR derived from HIV-1 trans-activating regulatory protein. The peptide (YGRKKRRQRRRGTSNSQKYMSFTDKSA) was synthesized in the proteomics core lab in Research Resource Centre at University of Illinois at Chicago (UIC), USA and was confirmed by mass spectrometry.
Open in Who Shared Issue with article?

Stereospecific rapid activation of Transcription Factor EB (TFEB) by Levacetylleucine (NALL)

|
By Antony Galione, Frances M. Platt, Grant Churchill, Marc Patterson
| BioRxiv
Abstract N-acetyl L-leucine (NALL, USAN or levacetylleucine, INN or trade name Aqneursa) is an FDA-approved agent for the treatment of Niemann-Pick disease type C (NPC). The N-acetyl group renders the compound a prodrug of L-leucine, making it a substrate for membrane-spanning monocarboxylate transporters (MCTs), which are ubiquitously expressed delivering NALL to all tissues with high capacity, including to the central nervous system.
Open in Who Shared Issue with article?

Unexpected differences in the pharmacokinetics of N-acetyl-DL-leucine enantiomers after oral dosing and their clinical relevance

|
By Grant Churchill, Michael Strupp, Antony Galione
| PLOS
Loading metrics Open Access Peer-reviewed Research Article Grant C. Churchill , Michael Strupp, Antony Galione, Frances M. Platt Grant C. Churchill, Michael Strupp, Antony Galione, Frances M.
Open in Who Shared Issue with article?
See all 3 articles

Awards

Associated Press Sports Editors' Red Smith Award

View Award